

WE SUCCEEDED WITH TRANSGENIC ANIMAL TECHNOLOGIES

We enable biotech and pharmaceutical researchers to discover and optimize successful antibody lead candidates by leveraging IPA's advanced, proprietary technologies and years of experience to yield greater candidate diversity in a streamlined, in-house environment eliminating the need for multiple CRO outsourcing.



- Accelerated human antibody discovery
- Successful transgenic projects with B cell Select™, Phage Display and Hybridoma
- Approved CRO for each of the premier transgenic animal platforms

Request a **Free Target Analysis** with our Experts.

Contact: solutions@immunoprecise.com | +31 412 846 000 or +1 800-620-4187

DeepDisplay™ Case Study




Transmembrane Therapeutic Target

Deep Display™: Phage Display featuring OmniAb® Transgenic Rodents

Objective

Generation of fully-human, therapeutic lead antibody candidates with mouse, cyno and human cross-reactivity against a target, comparing phage display technology with hybridoma-based discovery for a large pharmaceutical company.

Project Phases



DeepDisplay™ Results

- Five out of eight rodents showed a good immune response against both human and cyno recombinant target protein
- Screening of **360** randomly picked monoclonals from top five selection outputs resulted in a panel of antibodies with diverse target-reactivity profiles
- 20% of the screened monoclonals showed full cross-reactivity toward plate-immobilized and, importantly, cell-associated human, cyno and mouse target
- Sequence analysis of the top **90 phage** clones showed **75 phage-derived unique antibody variable domain sequences**

Conclusion

- A panel of sequence diverse, human lead antibodies specifically directed against a transmembrane target protein was generated in relatively short time span
- DeepDisplay™, the powerful and unique antibody discovery platform, yielded a diverse pool of antibody lead candidates with broad species cross-reactivity

Sequence Diversity Analysis

